Download
s10585-020-10058-8.pdf 1,16MB
WeightNameValue
1000 Titel
  • Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer
1000 Autor/in
  1. Voß, Hannah |
  2. Wurlitzer, Marcus |
  3. Smit, Daniel J. |
  4. Ewald, Florian |
  5. Alawi, Malik |
  6. Spohn, Michael |
  7. Indenbirken, Daniela |
  8. Omidi, Maryam |
  9. David, Kerstin |
  10. Juhl, Hartmut |
  11. Simon, Ronald |
  12. Sauter, Guido |
  13. Fischer, Lutz |
  14. Izbicki, Jakob R. |
  15. Molloy, Mark P. |
  16. Nashan, Björn |
  17. Schlüter, Hartmut |
  18. Jücker, Manfred |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-10-24
1000 Erschienen in
1000 Quellenangabe
  • 37(6):649-656
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s10585-020-10058-8 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666585/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Colorectal cancer (CRC) patients suffer from the second highest mortality among all cancer entities. In half of all CRC patients, colorectal cancer liver metastases (CRLM) can be observed. Metastatic colorectal cancer is associated with poor overall survival and limited treatment options. Even after successful surgical resection of the primary tumor, metachronous liver metastases occur in one out of eight cases. The only available curative intended treatment is hepatic resection, but metachronous CRLM frequently recur after approximately 1 year. In this study, we performed a proteome analysis of three recurrent liver metastases of a single CRC patient by mass spectrometry. Despite surgical resection of the primary CRC and adjuvant chemotherapy plus cetuximab treatment, the patient developed three metachronous CRLM which occurred consecutively after 9, 21 and 31 months. We identified a set of 1132 proteins expressed in the three metachronous CRLM, of which 481 were differentially regulated, including 81 proteins that were associated with the extracellular matrix (ECM). 56 ECM associated proteins were identified as upregulated in the third metastasis, 26 (46%) of which were previously described as negative prognostic markers in CRC, including tenascin C, nidogen 1, fibulin 1 and vitronectin. These data may reflect an ascending trend of malignancy from the first to the third metachronous colorectal cancer liver metastasis. Additionally, the results indicate different ECM phenotypes for recurrent metachronous metastasis, associated with different grades of malignancy and highlights the importance of individual analysis of molecular features in different, consecutive metastatic events in a single patient.
1000 Sacherschließung
lokal Extracellular Matrix/pathology [MeSH]
lokal Leucovorin/administration
lokal ECM signatures
lokal Colorectal liver metastasis
lokal Extracellular Matrix/metabolism [MeSH]
lokal Neoplasm Recurrence, Local/pathology [MeSH]
lokal Neoplasms, Second Primary/pathology [MeSH]
lokal Colorectal cancer
lokal ECM
lokal Colorectal Neoplasms/metabolism [MeSH]
lokal Proteomics
lokal Prognostic factor
lokal Liver Neoplasms/metabolism [MeSH]
lokal Male [MeSH]
lokal Extracellular Matrix Proteins/metabolism [MeSH]
lokal Mass Spectrometry [MeSH]
lokal Metachronous liver metastasis
lokal CRC
lokal CRLM
lokal Fluorouracil/administration
lokal Neoplasms, Second Primary/metabolism [MeSH]
lokal Neoplasms, Second Primary/drug therapy [MeSH]
lokal Humans [MeSH]
lokal Colorectal Neoplasms/drug therapy [MeSH]
lokal Middle Aged [MeSH]
lokal Neoplasm Recurrence, Local/metabolism [MeSH]
lokal Antineoplastic Combined Chemotherapy Protocols/administration
lokal Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH]
lokal Organoplatinum Compounds/administration
lokal Research Paper
lokal Proteome/metabolism [MeSH]
lokal Extracellular matrix
lokal Liver Neoplasms/secondary [MeSH]
lokal Colorectal Neoplasms/pathology [MeSH]
lokal Neoplasm Recurrence, Local/drug therapy [MeSH]
lokal Liver Neoplasms/drug therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/Vm-DnywgSGFubmFo|https://frl.publisso.de/adhoc/uri/V3VybGl0emVyLCBNYXJjdXM=|https://orcid.org/0000-0002-3190-9511|https://frl.publisso.de/adhoc/uri/RXdhbGQsIEZsb3JpYW4=|https://frl.publisso.de/adhoc/uri/QWxhd2ksIE1hbGlr|https://frl.publisso.de/adhoc/uri/U3BvaG4sIE1pY2hhZWw=|https://frl.publisso.de/adhoc/uri/SW5kZW5iaXJrZW4sIERhbmllbGE=|https://frl.publisso.de/adhoc/uri/T21pZGksIE1hcnlhbQ==|https://frl.publisso.de/adhoc/uri/RGF2aWQsIEtlcnN0aW4=|https://frl.publisso.de/adhoc/uri/SnVobCwgSGFydG11dA==|https://frl.publisso.de/adhoc/uri/U2ltb24sIFJvbmFsZA==|https://frl.publisso.de/adhoc/uri/U2F1dGVyLCBHdWlkbw==|https://frl.publisso.de/adhoc/uri/RmlzY2hlciwgTHV0eg==|https://frl.publisso.de/adhoc/uri/SXpiaWNraSwgSmFrb2IgUi4=|https://frl.publisso.de/adhoc/uri/TW9sbG95LCBNYXJrIFAu|https://frl.publisso.de/adhoc/uri/TmFzaGFuLCBCasO2cm4=|https://frl.publisso.de/adhoc/uri/U2NobMO8dGVyLCBIYXJ0bXV0|https://orcid.org/0000-0003-2176-6526
1000 Hinweis
  • DeepGreen-ID: e617c293a6c34fff90b50aaee68b6d21 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6468308.rdf
1000 Erstellt am 2023-11-17T15:35:34.461+0100
1000 Erstellt von 322
1000 beschreibt frl:6468308
1000 Zuletzt bearbeitet 2023-12-01T07:41:24.536+0100
1000 Objekt bearb. Fri Dec 01 07:41:24 CET 2023
1000 Vgl. frl:6468308
1000 Oai Id
  1. oai:frl.publisso.de:frl:6468308 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source